$11.73
0.38[3.35%]
At close: Apr 15
$11.73
0[0.00%]
After Hours: 6:48AM EDT
Adverum Biotechnologies
(NASDAQ:ADVM)Adverum Biotechnologies Stock (NASDAQ:ADVM), Analyst Ratings, Price Targets, Predictions
Adverum Biotechnologies Inc has a consensus price target of $3.44, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Chardan Capital, RBC Capital, and Mizuho on March 19, 2024, March 19, 2024, and February 6, 2024. With an average price target of $3.33 between Chardan Capital, RBC Capital, and Mizuho, there's an implied -71.58% downside for Adverum Biotechnologies Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
RBC Capital
Mizuho
Truist Securities
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Adverum Biotechnologies
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -65.9% | Chardan Capital | Daniil Gataulin | → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -82.95% | RBC Capital | Luca Issi | $30 → $20 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -65.9% | Mizuho | Graig Suvannavejh | $20 → $40 | Maintains | Buy | Get Alert |
| 11/02/2023 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -82.95% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Buy | Get Alert |
| 09/05/2023 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -48.85% | Truist Securities | Joon Lee | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -65.9% | Chardan Capital | Daniil Gataulin | $20 → $40 | Upgrade | Neutral → Buy | Get Alert |
| 03/07/2023 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -82.95% | Ladenburg Thalmann | Aydin Huseynov | → $20 | Initiates | → Buy | Get Alert |
| 11/11/2022 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -82.95% | Chardan Capital | Daniil Gataulin | $25 → $20 | Maintains | Neutral | Get Alert |
| 11/11/2022 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -74.42% | RBC Capital | Luca Issi | $50 → $30 | Maintains | Sector Perform | Get Alert |
| 08/12/2022 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -78.69% | Chardan Capital | Daniil Gataulin | $30 → $25 | Maintains | Neutral | Get Alert |
| 07/07/2022 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -65.9% | Truist Securities | Joon Lee | $30 → $40 | Upgrade | Hold → Buy | Get Alert |
| 07/23/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -74.42% | Chardan Capital | Geulah Livshits | $50 → $30 | Maintains | Neutral | Get Alert |
| 07/23/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -74.42% | Cantor Fitzgerald | Alethia Young | $230 → $30 | Downgrade | Overweight → Neutral | Get Alert |
| 07/23/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -82.95% | SVB Leerink | Mani Foroohar | $50 → $20 | Maintains | Market Perform | Get Alert |
| 05/03/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -57.37% | SVB Leerink | Mani Foroohar | → $50 | Downgrade | Outperform → Market Perform | Get Alert |
| 04/29/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -48.85% | RBC Capital | Luca Issi | → $60 | Downgrade | Outperform → Sector Perform | Get Alert |
| 04/29/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -57.37% | Chardan Capital | Gbola Amusa | $200 → $50 | Downgrade | Buy → Neutral | Get Alert |
| 04/29/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -23.27% | Truist Securities | Joon Lee | $300 → $90 | Downgrade | Buy → Hold | Get Alert |
| 04/29/2021 | ADVM | Buy Now | Adverum Biotechnologies | $11.73 | -6.22% | SVB Leerink | Mani Foroohar | $210 → $110 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Adverum Biotechnologies (ADVM)?
The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by Chardan Capital on March 19, 2024. The analyst firm set a price target for $4.00 expecting ADVM to fall to within 12 months (a possible -65.90% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
The latest analyst rating for Adverum Biotechnologies (NASDAQ: ADVM) was provided by Chardan Capital, and Adverum Biotechnologies reiterated their buy rating.
When was the last upgrade for Adverum Biotechnologies (ADVM)?
The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.
When was the last downgrade for Adverum Biotechnologies (ADVM)?
The last downgrade for Adverum Biotechnologies Inc happened on July 23, 2021 when Cantor Fitzgerald changed their price target from $23 to $3 for Adverum Biotechnologies Inc.
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a reiterated with a price target of $0.00 to $4.00. The current price Adverum Biotechnologies (ADVM) is trading at is $11.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.